Markets
markets

Intel trading overtakes Nvidia as White House pushes for TSMC deal

One of the big stories of the week has been the upsurge in Intel — both in terms of trading activity and prices. It’s up almost 25% this week despite a drop Friday.

The jump came after indications that the Trump administration was pushing to use Intel, which received billions under the Biden administration’s CHIPS Act, as its vehicle for ensuring US AI chip production.

That story is consistent with one reported Friday by Bloomberg, in which reporters wrote:

Taiwan Semiconductor Manufacturing Co. is considering taking a controlling stake in Intel Corp.’s factories at the request of Trump administration officials, a person familiar with the matter said, as the president looks to boost American manufacturing and maintain US leadership in critical technologies.

Trump’s team raised the idea of a deal between the two companies in recent meetings with officials from the Taiwanese chipmaker, the person said, and TSMC was receptive. It’s unclear whether Intel is open to a transaction.

This follows an earlier report saying that TSMC is considering building an advanced packaging plant in the US amid pressure from Trump.

Any talk of a deal might be preliminary to fanciful. See, for instance, Trump’s first-term push to bring a Foxconn manufacturing plant to Wisconsin along with $10 billion of investment and 13,000 jobs.

But the market seems happy to buy the Intel rumor here.

The once iconic American chip company was the top traded stock, in terms of share volumes, in the S&P 500 on Friday, beating even the trading monster that is Nvidia. (Though, of course, the total value of Nvidia shares is far higher.)

That story is consistent with one reported Friday by Bloomberg, in which reporters wrote:

Taiwan Semiconductor Manufacturing Co. is considering taking a controlling stake in Intel Corp.’s factories at the request of Trump administration officials, a person familiar with the matter said, as the president looks to boost American manufacturing and maintain US leadership in critical technologies.

Trump’s team raised the idea of a deal between the two companies in recent meetings with officials from the Taiwanese chipmaker, the person said, and TSMC was receptive. It’s unclear whether Intel is open to a transaction.

This follows an earlier report saying that TSMC is considering building an advanced packaging plant in the US amid pressure from Trump.

Any talk of a deal might be preliminary to fanciful. See, for instance, Trump’s first-term push to bring a Foxconn manufacturing plant to Wisconsin along with $10 billion of investment and 13,000 jobs.

But the market seems happy to buy the Intel rumor here.

The once iconic American chip company was the top traded stock, in terms of share volumes, in the S&P 500 on Friday, beating even the trading monster that is Nvidia. (Though, of course, the total value of Nvidia shares is far higher.)

More Markets

See all Markets
markets
Luke Kawa
9/5/25

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.